A 57-Year-Old Man Diagnosed with Non-Clear Cell, Renal Cell Carcinoma (nccRCC)

Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.

Dr. Motzer discusses his view on the appropriateness of the initial therapy for this nccRCC patient, including key factors he considers when deciding on initial treatment.

Dr. Motzer reviews the efficacy and safety data from the KEYNOTE-427 trial.

Dr. Motzer provides his perspective on emerging efficacy and safety data updates from KEYNOTE-B61, and Nivolumab+Cabozantinib, evaluating combination regimens in nccRCC.

Dr. Motzer compares combination IO + TKIs to single agent ICI or TKI therapy regarding efficacy in nccRCC patients.

Dr. Motzer discusses the major challenges and mitigation strategies for managing high-grade adverse events with nccRCC regimens.

Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.

Dr. Motzer shares his viewpoint on quality-of-life preservation observed with different regimens for nccRCC patients.

Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.